- Severe Bacterial Infections
- Severe Urinary tract infection
- Tuberculosis Infection
- Respiratory Tract Infection Bacterial
- Mycobacterium avium complex infection
- Neonatal Sepsis
- Nosocomial Pneumonia
Mechanism of action-
Amikacin is an aminoglycoside antibiotic. Aminoglycosides bind to the bacteria, causing misreading of t-RNA, leaving bacteria unable to synthesize proteins vital to their growth. It binds to bacterial 30S ribosomal subunits and interferes with mRNA binding and tRNA acceptor sites, interfering with bacterial growth. This leads to disruption of normal protein synthesis and production of non-functional or toxic peptides Aminoglycosides are useful mainly in the treatment infections involving aerobic, Gram-negative bacteria, such as Pseudomonas, Acinetobacter, and Enterobacter. In addition, some mycobacteria, including the bacteria that cause tuberculosis, are susceptible to aminoglycosides.
Pharmacokinetics-
After I.M injection, it is rapidly absorbed and the volume of distribution is 24L. The plasma protein binding is equal to or less than 10%. The drug is eliminated by kidney and the half-life is 2-3 hours.
Common side effect of amikacin includes:
-
Diarrhea
- Hearing loss
- Spinning sensation (vertigo)
- Numbness
- Skin tingling
- Muscle twitching and convulsions
- Dizziness
- Ringing or roaring in the ears
This injection should not be used in the following conditions:
- Pregnancy
- Renal impairment
- Myasthenia gravis
- Allergic to aminoglycosides
Following drugs may interact with amikacin:
-
Aspirin
- Ceftriaxone
- Gentamicin
- Kanamycin
- Lidocaine
- Vancomycin
- Warfarin